Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Annalisa Ruggeri; Liesbeth C De Wreede; Carlheinz R Müller; Pietro Crivello; Edouard F Bonneville; Effie W Petersdorf; Gerard Socié; Valérie Dubois; Riitta Niittyvuopio; Juha Peräsaari; Ibrahim Yakoub-Agha; Jan J Cornelissen; Lotte Wieten; Tobias Gedde-Dahl; Edouard Forcade; Charles R Crawley; Steven G E Marsh; Virginie Gandemer; Eleni Tholouli; Claude-Eric Bulabois; Anne Huynh; Goda Choi; Eric Deconinck; Maija Itäla-Remes; Stig Lenhoff; Mats Bengtsson; Jan-Erik Johansson; Gwendolyn Van Gorkom; Jorinde D Hoogenboom; Luca Vago; Vanderson Rocha; Chiara Bonini; Christian Chabannon; Katharina Fleischhauer

doi:10.3324/haematol.2021.280055

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Haematologica. 2023 Feb 1;108(2):645-652. doi: 10.3324/haematol.2021.280055.

Authors

Annalisa Ruggeri¹, Liesbeth C De Wreede², Carlheinz R Müller³, Pietro Crivello⁴, Edouard F Bonneville², Effie W Petersdorf⁵, Gerard Socié⁶, Valérie Dubois⁷, Riitta Niittyvuopio⁸, Juha Peräsaari⁹, Ibrahim Yakoub-Agha¹⁰, Jan J Cornelissen¹¹, Lotte Wieten¹², Tobias Gedde-Dahl¹³, Edouard Forcade¹⁴, Charles R Crawley¹⁵, Steven G E Marsh¹⁶, Virginie Gandemer¹⁷, Eleni Tholouli¹⁸, Claude-Eric Bulabois¹⁹, Anne Huynh²⁰, Goda Choi²¹, Eric Deconinck²², Maija Itäla-Remes²³, Stig Lenhoff²⁴, Mats Bengtsson²⁵, Jan-Erik Johansson²⁶, Gwendolyn Van Gorkom²⁷, Jorinde D Hoogenboom²⁸, Luca Vago¹, Vanderson Rocha²⁹, Chiara Bonini¹, Christian Chabannon³⁰, Katharina Fleischhauer³¹

Affiliations

¹ San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation Unit, Milan, Italy; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden.
² Leiden University Medical Center, Leiden.
³ Zentrales Knochenmarkspender-Register Deutschland, Ulm.
⁴ Institute for Experimental Cellular Therapy, University Hospital Essen, Essen.
⁵ Fred Hutchinson Cancer Research Center, Seattle.
⁶ Hôpital St. Louis, Paris.
⁷ Histocompatibility Laboratory, EFS Lyon.
⁸ HUCH Comprehensive Cancer Center, Helsinki.
⁹ Clinical Laboratory Services, Histocompatibility Testing, Finnish Red Cross Blood Service, Helsinki.
¹⁰ CHU de Lille, Lille.
¹¹ Erasmus MC Cancer Institute, Rotterdam.
¹² Transplantation Immunology, Maastricht University Medical Center, Maastricht.
¹³ Oslo University Hospital, Rikshospitalet, Oslo.
¹⁴ CHU Bordeaux, Pessac.
¹⁵ Addenbrookes Hospital, Cambridge.
¹⁶ Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London,.
¹⁷ Centre Hospitalier Universitaire de Rennes, Rennes.
¹⁸ Manchester Royal Infirmary, Manchester.
¹⁹ CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble.
²⁰ CHU - Institut Universitaire du Cancer Toulouse, Toulouse.
²¹ University Medical Center Groningen (UMCG), Groningen.
²² Hopital Jean Minjoz, Besancon.
²³ Turku University Hospital, Turku.
²⁴ Skanes University Hospital, Lund.
²⁵ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
²⁶ Sahlgrenska University Hospital, Goeteborg.
²⁷ University Hospital Maastricht, Maastricht.
²⁸ EBMT Leiden Study Unit, Leiden.
²⁹ Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31) of the Service of Hematology and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, SP.
³⁰ Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, The Netherlands; Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille.
³¹ Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, The Netherlands; Institute for Experimental Cellular Therapy, University Hospital Essen, Essen. [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Alleles
Graft vs Host Disease* / etiology
HLA-DP beta-Chains / genetics
Hematopoietic Stem Cell Transplantation*
Histocompatibility Testing
Humans
Unrelated Donors

Substances

HLA-DPB1 antigen
HLA-DP beta-Chains

Grants and funding

Funding: This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG FL 843/1-1), the Deutsche José Carreras Leukämie Stiftung (DJCLS R 15-02; DJCLS 20R/2019), and the Joseph-Senker Stiftung to KF, and the DKMS (DKMS-SLS-MHG-2018-01) to PC.